 | Up a level |
Journal Article
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B., V, Blohmer, J-U, Grischke, E-M, Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2019). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol., 30 (8). S. 1279 - 1289. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kuemmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A-R, von Minckwitz, G. and Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol., 29 (12). S. 2341 - 2348. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kuemmel, S., Rhiem, K., Warm, M., Fasching, P. A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G. and Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). Ann. Oncol., 29. S. 60 - 61. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
von Minckwitz, G., Timms, K., Untch, M., Elkin, E. P., Hahnen, E., Fasching, P. A., Schneeweiss, A., Salat, C. T., Rezai, M., Blohmer, J-U, Zahm, D-M, Jackisch, C., Gerber, B., Klare, P., Kummel, S., Paepke, S., Schmutzler, R., Chau, S., Reid, J., Hartman, A-R, Nekljudova, V., Weber, K. E. and Loibl, S. (2017). Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445